Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionLysophosphatidic acid receptor 1 (LPAR1; EDG2; LPA1) and LPA3 receptor antagonist
Molecular Target Lysophosphatidic acid receptor 1 (LPAR1) (EDG2) (LPA1) ; Lysophosphatidic acid receptor 3 (LPAR3) (EDG7) (LPA3)
Mechanism of ActionLysophosphatidic acid receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationScleroderma
Indication DetailsTreat skin manifestation of scleroderma; Treat systemic sclerosis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today